Allergy-focused drugmaker Aimmune Therapeutics Inc. closed its underwritten public offering of 5.5 million common shares at $32 each with gross proceeds of $176 million.

Net proceeds from the offering are about $164.2 million. The company has also granted underwriters an option to buy up to 825,000 additional shares.

Aimmune recently shared phase 3 data for its most developed product, a peanut allergy medicine that showed effectiveness among 67.2% of patients. It announced the stock offering later that same day.

Bank of America Merrill Lynch, Cantor Fitzgerald & Co. and Piper Jaffray & Co. acted as joint book-running managers for the offering, while Credit Suisse and RBC Capital Markets also acted as book-running managers. Roth Capital Partners and Wedbush PacGrow were co-managers for the offering.